Zymeworks Inc. Appoints New Executives and Board Member

Reuters01-12
Zymeworks Inc. Appoints New Executives and Board Member

Zymeworks Inc. has announced several management changes, including the appointment of Brian Cherry to the Board of Directors and the promotion of Sabeen Mekan to Chief Medical Officer effective February 1, 2026. Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer. Five new Vice Presidents have been appointed: Charles Chen (Translational Sciences), Shrinal Inamdar (Investor Relations), Diana Papove (Corporate Communications), Victoria Spencer (Treasury and Tax), and Lingxing Zheng (Regulatory Affairs). Leone Patterson, Chief Financial and Business Officer, and Daniel Dex, General Counsel, will depart during the first quarter of 2026. Kenneth Galbraith has assumed the role of Acting Chief Financial Officer until a replacement is found. Additional promotions include Laura O'Connor to Senior Vice President and Chief Human Resources Officer, Bijal Desai to Senior Vice President, Finance, and Lindsey Foulkes to Senior Vice President, Corporate Development and Strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623451-en) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment